Lisa McDougall

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

John H. Krystal, Walid Abi‐Saab, Edward Perry et al. · Psychopharmacology · 2004 · 272 citations

Psychiatry, Brain Function, Medicine +11

Biodistribution, Pharmacokinetics, and Dosimetry of ¹⁷⁷Lu-, ⁹⁰Y-, and ¹¹¹In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist ¹⁷⁷Lu-DOTATATE: The Mass Effect

Guillaume Nicolas, Rosalba Mansi, Lisa McDougall et al. · Journal of Nuclear Medicine · 2017 · 141 citations · Full text

Changes in circulating hormone concentrations, testes histology and testes ultrasonography during sexual maturation in beef bulls

A.C.O. Evans, Roger A. Pierson, A. García et al. · Theriogenology · 1996 · 118 citations · Full text

Spermatogenesis, Fertility, Gynecology +25

Cholecystokinin 2 Receptor Agonist ¹⁷⁷Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study

Christof Rottenburger, Guillaume Nicolas, Lisa McDougall et al. · Journal of Nuclear Medicine · 2019 · 87 citations · Full text

First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum

Julia Fricke, Frida Westerbergh, Lisa McDougall et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2024 · 37 citations · Full text

Metastatic Neuroendocrine Tumour, Endocrine Oncology, Surgical Oncology +7